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Abstract: Clinical laboratories are strong, integral partners in personalized health care. 
  Laboratory databases hold a vast amount of data on human phenotypes, genotypes, biomark-
ers, progression of disease, and response to therapy. These structured and unstructured free 
text data are critical for patient care and a resource for personalized medicine and translational 
research. Laboratory data are integrated into many electronic medical records that provide 
“summary reports” and “trending” to visualize longitudinal patient data. Recent advances in 
ophthalmology such as gene therapy, cell therapy using stem cells, and also retinal prosthesis 
explore the potential of translational research marking a new era in research into the diagnosis 
and treatment of eye diseases.
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Introduction
Scientific research is traditionally divided into two categories: basic research and 
applied research. Basic research is needed to provide a better understanding of 
normal conditions vs disease, but it does not directly translate that knowledge into 
useful clinical applications. Translational research is the advancement of science 
applied to the development of new diagnostic tests, drugs and/or intervention tech-
niques for patients with an established understanding of their disease development 
and progression.
The main goal of translational research is to integrate advances in biotechnology in 
clinical trials, that is, furthering research from the bench to the bedside (Figure 1).
The observations of clinical investigators on the nature and progression of diseases 
direct basic scientific research. Researchers use clinical samples to study the diagnosis, 
the expression of biomarkers, differences between normal and disease conditions, and 
responses to therapy. Basic scientists then provide to clinicians new treatment strategies 
based on laboratory data. This constant feedback assists in the discovery of disease 
biomarkers and drug targets, resulting in a more rational development of medications 
and improves the effectiveness of therapeutic agents.
Translational research also enables faster development of potential therapies, 
reducing the time between the identification of drug targets and the availability of clini-
cally relevant treatment options. Currently, the completion of all phases of preclinical 
testing and clinical trials of a single drug takes 7–12 years, but the great amount of 
translational research being conducted around the world is a promising sign for faster 
progress in the near future.1
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Generally, the first phase of research explores what is 
needed in order to treat a disease so that potential treatments 
can be developed from basic laboratory research and to test 
the safety and efficacy of the medicines developed. The con-
cepts involved in this phase form the basis of evidence-based 
practice and the creation of clinical guidelines. In relation to 
drug development, the term “from the bench to bedside” is 
properly employed. Many pharmaceutical companies have 
created teams of professionals to work with translational 
medicine so that the interaction between basic research and 
clinical medicine is facilitated, particularly for clinical trials. 
This is already occurring with the development of biological 
products specifically designed for autoimmune diseases. 
Thus, these days, the evaluation of therapies involves such 
diverse areas as psychology, physical therapy, and   nutrition. 
The second phase of studies examines discoveries in clini-
cal sciences and evaluates the effectiveness and safety of 
interventions. Hence, Phase 1 studies are transferred to 
practical applications in real life environments and day-
to-day situations when different demographic factors and 
priorities can change clinical decisions and responses to 
treatment. Research in this phase plays a very informative 
role by providing information on the needs, acceptability, 
efficacy, and cost-effectiveness for the creation of health 
care policies that promote good management and use of 
resources. Particularly in the modern world in major eco-
nomic recession, these needs should challenge the environ-
ment created by the restricted view often seen in the setting 
of clinical trials.2,3
Phase III of translational research adds information 
  necessary to convert treatment and preventive strategies, 
which have proven their effectiveness and cost-effectiveness 
in Phase 2, as the basis of more stringent, albeit more exten-
sive and evidence-based government policies. These policies 
require different research processes to evaluate settings with 
more complex interactions. They involve a process of sus-
tainability that relies on approaches that require continuous 
refinement and methodological improvements.
As a consequence, research and translational medicine 
have personalized medicine.
Personalized medicine, as a term, evolved to indicate that 
the results of various forms of genomic analysis are applied 
to tailor medical care for a specific patient with obvious 
advantages that supplement, but do not replace, traditional 
clinical medicine. These advantages include the possibility 
of predicting susceptibility for a disease and, as a result, 
allow more detailed screening or prophylactic (preventative) 
treatment. Personalized medicine also offers the potential 
for diagnosis of diseases at an early stage when treatment is 
often more effective and sequelae may be minimized. This 
is particularly true with respect to cancer. Potential beneficia-
ries of these novel technologies will primarily be our patients 
but medical care institutions will also benefit. There are vast 
business opportunities for companies that develop diagnoses, 
drugs, or methods for data analysis. Already several medical 
schools have developed institutes, programs, or curricula 
focused on personalized medicine. Companies have been 
formed   employing marketing analysis that purports to predict 
one’s risk of developing a myriad of diseases ranging from 
Alzheimer’s disease and diabetes to baldness in men.2–5
Translational medicine has also had a great impact 
in   ophthalmology. Some examples of research using this 
concept that will certainly be part of our everyday clinical 
practice in the near future are listed below.
Genetic testing and gene therapy  
in retinal diseases
The era of molecular ophthalmology began in 1985 with the 
discovery of the retinoblastoma gene.6 Since then, hundreds 
of other genes responsible for a variety of important diseases 
have been discovered, including genes associated with age-
related macular degeneration (AMD), glaucoma, congenital 
cataract, both syndromic and non-syndromic forms of photo-
receptor degeneration, multiple macular dystrophies, corneal 
dystrophies, vitreoretinopathies, and optic neuropathies. The 
discovery of genetic causes of diseases allows individual-







Figure 1 Scheme showing translational research conducted by our research group 
(Clinicaltrial.gov:  NCT01068561).  This  clinical  trial  was  about  the  use  of  bone 
marrow-derived stem cell for the treatment of retinal dystrophy. The patient is 
examined at the research center (A). The bone marrow is collected for bone marrow 
transplantation (B). The material collected is taken to the cell therapy laboratory for 
stem cell separation (C). Stem cells are injected into the patient’s eye in an operating 
room (D). The patient is again evaluated at the research center (A).
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in   clinical diagnosis and prognosis and in counseling. In 
addition, individuals who are found to carry known disease-
causing mutations can be enrolled in clinical trials of new 
therapies or carefully studied to fully explore the behavior 
of their disease over time.7,8 Samples from patients who lack 
mutations of known disease-causing genes can also serve as 
a valuable resource for scientists who seek to find additional 
disease-causing genes.9
Experiments to discover genes implicated in different 
diseases have aided this research by providing an improved 
understanding of specific biologic pathways that, when out 
of balance, lead to disease or susceptibility for disease. Such 
pathways can become important targets for therapeutic agents 
and scientists have been very creative in devising treatment 
specifically aimed at these targets.9
For example, the discovery that the ABCA4 gene is 
involved in transporting vitamin A derivatives from outer 
segment disks led to the discovery that vitamin A inhibitors, 
such as fenretinide, inhibit the accumulation of lipofuscin in 
animal models of Stargardt’s disease.10,11 The identification 
of the role of vascular endothelial growth factor in choroidal 
neovascularization led to the development of therapeutic 
antibodies (eg, ranibizumab and bevacizumab) to combat the 
main blinding complications of AMD. Growth factors and 
neuroprotective agents have also been used to reduce the rate 
of apoptotic response to inherited cellular abnormalities.12,13 
In recent years, gene-replacement therapy, therapeutic stem 
cells, and retinal prostheses have changed our approach to 
the treatment of genetic eye diseases.
More than a dozen recessive retinal diseases have been 
successfully treated with viral- or nanoparticle-based gene 
transfer in animal models.14 For example, one molecular 
form of Leber’s congenital amaurosis is caused by the lack 
of retinoid isomerase encoded by the RPE65 gene and 
vision was restored in a naturally occurring canine model 
of this disease using an adeno-associated viral vector to 
transfer a normal version of RPE65 to the retinal pigment 
epithelium.15 More recently, three different groups have 
extended this work to humans.16–18 Maguire and colleagues 
reported results in twelve patients who were treated with 
gene-replacement therapy. They observed visual improve-
ment in all twelve patients, with the greatest gains among 
younger patients.16
AMD is one of the best examples of a chronic degen-
erative genetic disease discovered to date; the hereditary 
factor is responsible for over 70% of the risk of developing 
the disease. Genetic testing can identify individuals with 
an increased risk for advanced AMD.19 Early   identification 
of   at-risk patients may prevent vision loss or slow the 
  progression of the disease through individualized treatment 
based on age and risk level. Frequent monitoring of individu-
als with an increased risk for advanced AMD may result in 
early detection of small choroidal neovascularization lesions 
and may lead to improved long-term visual acuity through 
early treatment. Additionally, environmental risk factors can 
be identified and modifications in lifestyle can be made to 
reduce the risk of developing advanced AMD.20
Both the candidate gene approach and genome-wide 
association studies (GWAS) have been used to elucidate 
sequence variations associated with AMD.21 Early work 
identified the potential importance of the complement family 
of inflammatory proteins in AMD on the basis of biochemical 
analysis of retinal drusen. As the genes and naturally occur-
ring sites of variability for all complement cascade proteins 
became known, statistically significant associations with 
neovascular AMD were identified. To date, convincing and 
reproducible associations of variations of the complement 
factor H (CFH), complement factor I (CFI), complement 
factor B (CFB), and complement component (CC3) genes 
have been demonstrated.22–25
Macula Risk (ArcticDx, Inc, Toronto, ON) is a commer-
cially available prognostic genetic test for patients diagnosed 
with early or intermediate AMD. Using an algorithm based on 
the complete combination of known AMD genes and history 
of smoking, the genetic test identifies those most likely to 
progress to advanced AMD with vision loss. Tested patients 
are stratified into risk categories; 20% of patients are pre-
dicted to have a higher than average lifetime risk of advanced 
AMD with 1% of those falling into a high-risk group with 
a predicted 65% chance of developing geographic atrophy 
or choroidal neovascularization. The ability to identify at-
risk patients allows physicians to tailor a more appropriate 
management plan for individual patients.20
Stem cell therapy in retinal diseases
Several important cell types in the eye have little if any capac-
ity for endogenous regeneration and as a result the only viable 
treatment option for patients with hereditary disorders that 
involve the loss of such cells is some type of cell replacement 
therapy. Although the replacement of highly differentiated 
cells, such as photoreceptors, poses challenges, a number 
of recent experiments suggest that the use of stem cells to 
achieve such a goal is now feasible.9
Distinct stem cell types have been established from 
embryos and identified in fetal tissues and umbilical cord 
blood as well as in specific niches in many adult mammalian 
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tissues and organs such as bone marrow, brain, skin, eyes, 
heart, kidneys, lungs, gastrointestinal tract, pancreas, liver, 
breast, ovaries, and prostate.26
Stem cell-based therapy has been tested in animal models 
for several diseases, including neurodegenerative disorders, 
such as Parkinson disease, spinal cord injury, and multiple 
sclerosis. Replacing lost neurons which have not been physi-
ologically replaced is pivotal to therapeutic success. In the 
eye, degeneration of neural cells in the retina is a hallmark 
of such widespread ocular diseases as AMD and retinitis 
pigmentosa (RP). In these cases the loss of photorecep-
tors that occurs as a primary event (as in RP) or secondary 
to loss of retinal-pigment epithelium (in AMD) leads to 
blindness.26–28
Stem cells can potentially be used for both neuropro-
tection and cell replacement. Intravitreal delivery of neu-
rotrophic factors slows down photoreceptor degeneration 
in rodent models of RP and retinal ganglion cell loss in 
glaucoma models and optic nerve and optic tract trauma, 
but the effect may be temporary. Slow-release preparations 
and gene therapy approaches to induce retinal cells to secrete 
neurotrophic factors are two ways to induce longer-term 
effects. A third option is to use stem cells as long-term 
delivery agents, possibly encapsulated in a device because 
many stem cells either secrete neurotrophins naturally or can 
be genetically engineered to do so.29,30
Recently, some reports demonstrated the clinical feasi-
bility of the intravitreal administration of autologous bone 
marrow-derived mononuclear cells in patients with advanced 
degenerative retinopathies.31,32 More recently, our group 
conducted a prospective Phase I trial to investigate the safety 
of intravitreal bone marrow-derived mononuclear cells in 
patients with retinitis pigmentosa or cone–rod dystrophy, 
with promising results.33
In 2010, the US Food and Drug Administration granted 
Orphan Drug designation for RPE cells of Advanced Cell 
Technology, Inc to initiate its Phase I/II clinical trials using 
retinal pigment epithelial cells derived from human embry-
onic stem cells to treat patients with Stargardt’s Macular 
Dystrophy and in 2011 the company received a positive 
opinion from the Committee for Orphan Medicinal Products 
of the European Medicines Agency towards designation of 
this product as an orphan medicinal product for the treatment 
of Stargardt’s disease.34
Stem cells maintain the balance between somatic cell 
populations in several tissues and are responsible for organ 
regeneration. The remarkable progress of regenerative medi-
cine over the last few years is promising for the use of stem 
cells in the treatment of ophthalmic disorders. Based on this 
success, experimental and human studies of bone marrow-
derived stem cells have begun.
Research using stem cells opened another arm in trans-
lational research.
The need to use the lab, biologists, and clinical experts 
has created a multidisciplinary environment, which is a 
characteristic of translational medicine.
Retinal prosthesis technology
Retinal prosthesis technology is currently under development 
in more than 13 centers across five continents worldwide, 
although the technology used, and stages of development in 
the various groups, differ significantly.
Extensive efforts have been undertaken to develop 
artificial devices aimed at restoring some vision in blind 
individuals. Most of these devices use electrical currents to 
stimulate the visual pathway, thereby bypassing damaged 
structures.35–41 Briefly, these devices incorporate an image 
capture module (eg, a camera), a processor that transforms 
the captured image into a pattern of stimulating currents 
and an electrode array through which electrical currents are 
delivered to the target stimulation site (retina, optic nerve, or 
visual cortex). Among these, retinal prostheses are probably 
the most advanced as the first clinical trials are currently 
underway.36 Patients with advanced retinal degenerative 
diseases and their family members often actively seek 
information on the latest neuroprotective treatments aimed at 
slowing down the progression of their disease or rehabilita-
tive technologies that may restore their sight. Retina physi-
cians are faced with the task of explaining to patients the 
state of retinal prosthesis technology, including when it will 
become practical and what level of vision might be restored. 
While this may seem daunting, a systematic approach to 
categorizing retinal prosthesis technology greatly simplifies 
comprehension of this field.
A retinal prosthesis is a device that gathers visual 
information with an electronic detector, then processes 
and converts that image into a form of stimulation that 
the retina and brain can interpret as a form of vision. All 
retinal prostheses can be categorized according to three 
fundamental design features – detector type, stimulation 
type, and stimulation site.
Detectors for retinal prostheses can be complementary 
metal-oxide-semiconductor (CMOS) or charge-coupled 
device (CCD) chips found in webcams or camcorders to 
microphotodiodes that act as tiny solar cells, turning light 
directly into electrical current.36–41
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Most retinal prostheses under development today 
employ electrical current to stimulate the retina, producing 
  electrophosphenes. These are small, round, oval, or elongated 
spots of light produced when pulses of electrical current are 
applied to the retina.41
In an effort to develop a more naturalistic method of 
retinal stimulation, the collaborative groups at Wayne State 
University and Mayo Clinic are designing methods to deliver 
neurotransmitters to retinal neurons using microfluidic 
  technology. This approach leverages natural chemical visual 
channels within the retina and can stimulate or inhibit neu-
ronal firing, thus forming the basis for visual contrast. This 
technique employs the controlled delivery of neurotransmit-
ters to the retina in space and time, analogous to the way an 
inkjet printer puffs ink onto paper.41,42
The most critical component of the retinal prosthesis 
system is the tissue interface formed at the junction of the 
neurosensory retina and the stimulator.
Subretinal placement assures close proximity to the neu-
rosensory retina and obviates the need for tack fixation as 
the retina is draped over the stimulation sites. However the 
surgical approach is more complex as it requires a pars plana 
vitrectomy, formation of a localized retinal detachment bleb 
and trans-scleral, trans-choroidal incisions for the ab-externo 
insertion of the stimulator into the subretinal space. After inser-
tion, the retina is re-attached via internal tamponade.38,40
Retinal prosthesis technology has been under develop-
ment for more than two decades. Several different designs 
for retinal prostheses have had promising results in both 
animals and humans and one of these designs has recently 
been approved for clinical use in Europe.41,42
The junction of the fields of bioengineering, biomateri-
als, neurology, and ophthalmology has allowed transla-
tional research to develop a system of intraocular retinal 
prosthesis.
Conclusion
Translational medicine has been described as the integrated 
application of innovative pharmacology tools, biomarkers, 
clinical methods, clinical technologies, and study designs to 
improve the understanding of medical disorders. In medi-
cine, translational research offers an opportunity to apply 
the findings obtained in basic research to everyday clinical 
applications.
Translational medicine is the development of more useful 
methods that allow a better application of basic research-
based knowledge to the medical field as we are now seeing 
in the area of ophthalmology.
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